Omesar Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Omesar Plus, is an angiotensin II receptor blocker combined with a thiazide diuretic presented as a tablet for oral use. It treats hypertension and is used in adults who require blood pressure control.

GNH USA supplies Omesar Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omesar Plus is an antihypertensive medication that acts on the renin‑angiotensin‑aldosterone system to lower blood pressure. - Hypertension: helps achieve target blood pressure levels in patients with primary hypertension. - Hypertension with fluid retention: provides additional diuretic effect to reduce excess fluid. - High‑risk cardiovascular patients: used as part of combination therapy to lower cardiovascular risk.

Adverse reactions to Omesar Plus may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Severe electrolyte imbalance - Liver function abnormalities

Before starting Omesar Plus, patients should be evaluated for several safety considerations. - Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium and sodium levels before and during therapy. - Pregnancy: avoid use during pregnancy, especially the second and third trimesters. - Concomitant drugs: review other antihypertensives or potassium‑sparing agents. - Elderly patients: start at lower doses and monitor for orthostatic symptoms. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omesar Plus can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren: may cause excessive reduction in blood pressure and renal function. - Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyper‑kalemia. - Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect kidney function. - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, monitor for hypotension. - Antidiabetic drugs: may enhance glucose‑lowering effect, requiring dose adjustment.